Related Experiment Video
Updated: Sep 24, 2025
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
FLT3-targeted treatment for acute myeloid leukemia
Yasuyuki Arai1, SungGi Chi2, Yosuke Minami2
1Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Abstract:
Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are detected in approximately 30% of acute myeloid leukemia (AML). The high frequency of FLT3 mutations, along with their adverse effect on prognosis, makes FLT3 a promising therapeutic target, and has spurred development of FLT3 inhibitors. First-generation inhibitors, including midostaurin and sorafenib, lack specificity for FLT3 and act on multiple kinases, whereas second-generation inhibitors, including gilteritinib, and quizartinib, are highly specific to FLT3 and are more potent than first-generation inhibitors. Several FLT3 inhibitors have recently gained regulatory approval worldwide, and several others are under development. The advent of FLT3 inhibitors has changed the standard treatment for FLT3-mutated AML in the frontline and relapsed/refractory settings and contributed to improved outcomes for this formidable AML subtype. However, numerous unresolved issues remain owing to rapid changes in practice. These include identification of optimum FLT3 inhibitors and combination therapies, the role of maintenance therapy, and the indication for allogeneic hematopoietic cell transplantation. Furthermore, strategies to overcome resistance to FLT3 inhibitors must be pursued. Results of ongoing and future studies will improve our ability to use FLT3 inhibitors more effectively, which should provide significant benefits to a wider range of patients.
Insights
FLT3 inhibitors have transformed acute myeloid leukemia (AML) treatment, offering improved outcomes for FLT3-mutated AML. Further research is needed to optimize therapies and overcome resistance for better patient benefits.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene occur in ~30% of acute myeloid leukemia (AML) cases.
- FLT3 mutations are associated with a poor prognosis, making FLT3 a key therapeutic target in AML.
- Development of FLT3 inhibitors has advanced significantly, with approved first- and second-generation drugs.
Purpose of the Study:
- To review the current landscape of FLT3 inhibitors in AML treatment.
- To discuss the impact of FLT3 inhibitors on patient outcomes.
- To identify unresolved issues and future directions in FLT3-targeted therapy for AML.
Main Methods:
- Review of current literature on FLT3 inhibitors in AML.
- Analysis of the efficacy and safety of first- and second-generation FLT3 inhibitors.
- Discussion of clinical trial results and ongoing research.
Main Results:
- Second-generation FLT3 inhibitors (e.g., gilteritinib, quizartinib) show higher specificity and potency than first-generation agents.
- FLT3 inhibitors have improved treatment standards in both frontline and relapsed/refractory FLT3-mutated AML.
- Several FLT3 inhibitors are approved, with more under development, demonstrating clinical progress.
Conclusions:
- FLT3 inhibitors represent a significant therapeutic advance for FLT3-mutated AML.
- Key challenges include optimizing inhibitor selection, combination therapies, and managing resistance.
- Future research will focus on refining FLT3-targeted strategies to benefit more AML patients.
